(Q44928213)

English

Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Phase II study of an intensive combination chemotherapy with cisplatin, adriamycin, etoposide and cyclophosphamide (CAVE) in small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sculier JP

1

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Klastersky J

2

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Becquart D

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Vandermoten G

4

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

van Houtte P

5

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Rocmans P

6

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Thiriaux J

7

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Longeval E

8

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Ravez P

9

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Libert P

10

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

publication date

1 March 1988

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

European Journal of Cancer & Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

519-526

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Cisplatin, adriamycin, and etoposide (CAV) for remission induction of small-cell bronchogenic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC Lung Cancer Working Party (Belgium)

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy versus chemoimmunotherapy for small-cell undifferentiated carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Chest irradiation as an attempt to improve the response after induction chemotherapy in small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

VP-16 and cisplatin as first-line therapy for small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Late intensification in small-cell lung cancer: a phase I study of high doses of cyclophosphamide and etoposide with autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term survivors of small cell carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin, cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive chemotherapy in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of vindesine and VP16-213 in the palliation of poor-prognosis patients and elderly patients with small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined modality treatment of extensive small cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternating radiotherapy and chemotherapy schedules in small cell lung cancer, limited disease

1 reference

https://api.crossref.org/works/10.1016%2FS0277-5379%2898%2990032-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0277-5379(98)90032-3

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44928213&oldid=2057941060"